Kieron White

Postdoctoral researcher at Subklewe Lab - Translational Cancer Immunology | Bioinformatician

[Kieron White @_KieronWhite]

Dr. White!!😅 Delighted to be awarded my PhD after 4 years of hard work, filled with incredible memories and limited sleep! A huge thankyou to everyone who helped me get to this stage! A special thanks to my supervisor @NetByrne and Dr. Kate Connor for their endless support

[Kieron White @_KieronWhite]

Our e-poster (EXTH-64) is still available to view incase you missed us at the poster presentation!

[Kieron White @_KieronWhite]

Just back from #SNO2023 in beautiful Vancouver. Great conference with insightful discussions surrounding the importance of accurate GBM models for assessment of novel therapies. Very grateful for the funding bodies and collaborations for making this work possible

[Roel Verhaak @roelverhaak]

And another potential oncolytic virus response win for glioblastoma! Clinical trial links oncolytic immunoactivation to survival in glioblastoma https://t.co/N0vOhv7WFr

[Eric Topol @EricTopol]

If you're interested in how our immune system and immune-directed interventions interact with cancer, you'd be hard pressed to find a better, up-to-date review than this one
https://t.co/IXq08Zad2s @ImmunityCP @TurleyLabGNE . .

[RAMI @RAMIreland]

RAMI Research Awards, 25th Sept 2023, short-listed entries and winners. Congrats to all https://t.co/jpiE2bKcKB

[Kieron White @_KieronWhite]

Honoured to receive the @RAMIreland award for best oncology paper in 2022!A massive thank you to @NetByrne and all the incredible collaborations throughout my #GLIOTRAIN PhD @Glioresolve for making this possible.

You can read the paper here: https://t.co/QfDy4XsTKV

[Kieron White @_KieronWhite]

Great opportunity to discuss our data at the #CICON23 conference. Establishing a clinically relevant GBM model is critical to understand treatment response + ultimately translate novel TME targeting agents to the clinic

[Kieron White @_KieronWhite]

Excellent talk from @sautesfridm explaining the role of TLS and B cells in immunotherapy response at the #CICON conference in Milan. Exciting to see our recent TLS findings in GBM included!

[GLIORESOLVE @Glioresolve]

Great 1st Plenary meeting for the GLIORESOLVE network today. Welcoming our new students, catching up with some familiar faces and meeting some people in person for the first time 🙏 Looking forward to the next 3.5 years! @NetByrne @MSCActions @HorizonEU @HorizonEuropeIE

[Kieron White @_KieronWhite]

Delighted to have the opportunity to present at the @Glioresolve welcome meeting. Exciting times ahead!

[Annette Byrne @NetByrne]

Delighted to welcome @Glioresolve team to @RCSI_Irl for first in person meeting. Great to have Dr @KieronWhitey present scientific background to the project

[Dana-Farber News @DanaFarberNews]

“Seeing these patients do well on the trial has been really gratifying," said Patrick Wen, director of the center for neuro-oncology @DanaFarber. Read more in @WSJ about this treatment breakthrough for an intractable brain cancer, presented at #ASCO23:

https://t.co/qUaza9yUIu

[NEJM @NEJM]

Late breaking at #ASCO23: Mutations in isocitrate dehydrogenase 1 or 2 are common in low-grade glioma. The IDH inhibitor vorasidenib improved progression-free survival as compared with placebo. Full results of the INDIGO trial: https://t.co/qypyIPmdD0

[Prof Jochen Prehn @ProfJochen]

Great to see our three ⁦@PhysiologyRCSI⁩ PhD and MD students who graduated today from ⁦@RCSI_Irl⁩ with their supervisors as well as Heiko and Ina who support them during COVID and beyond! ⁦@NetByrne⁩ ⁦@PfeifferShona⁩

[RCSI @RCSI_Irl]

Today's @IrishTimes features a magazine dedicated to the pioneering work of the Beaumont RCSI @CancerCentreIre.
 
Read how the Centre is leading the fight against cancer with patient-partnered care informed by research.
 
Pick up a copy or read online: https://t.co/77H8ko7L8S

[Farshad Nassiri @FarshadNassiri]

excited to share results of first #clinicaltrial of oncolytic viral + immunotherapy for #GBM published in @naturemedicine
https://t.co/cF9a1KIBM9
@UofTNeuroSurge @UHN_Research @KBI_UHN @PMResearch_UHN

[Kieron White @_KieronWhite]

Very exciting to see our TME subtypes being applied to assess the outcome of oncolytic virus therapy in GBM. Interesting to see TME-Med appears to be associated with improved response to DNX-2401 + anti-PD1 treatment

[Nature Medicine @NatureMedicine]

A phase 1 trial of the #OncolyticVirus DNX-2401 followed by intravenous anti-PD-1 #Pembrolizumab in patients w/recurrent #Glioblastoma shows an encouraging clinical benefit rate & 12 months overall survival. https://t.co/EdJt0PQheU
@gelarehzadeh @FarshadNassiri

[Kieron White @_KieronWhite]

Final version of my thesis submitted, roll on graduation!🎓

[Kieron White @_KieronWhite]

A huge thankyou to the collaborators and funding bodies involved in this project and @EACRnews for the opportunity to present this work

[Kieron White @_KieronWhite]

Great opportunity presenting our poster where we have established a clinically relevant model of Mes GBM. Using subtype-specific models which more accurately mirror treatment response (+ TME) in patients will likely guide more effective therapeutic strategies #eacrImmunoOncology

[Kieron White @_KieronWhite]

Super thought-provoking first day at the immuno-oncology breakthroughs conference, located at the stunning la pedrera. Loaded up on tapas ready for day 2!
#eacrImmunoOncology